chevron_leftBack
As of 6 June 2026, Aptamer Group PLC has a market cap of $26.67M USD, ranking #35065 globally and #793 in the United Kingdom.
It ranks #3164 in the Healthcare sector, and #611 in the Biotechnology industry.
Key Stats
Market Cap
$26.67MUSD
19.87M GBP
Enterprise Value
$24.9MUSD
18.67M GBP
Revenue (TTM)
$1.85MUSD
1.38M GBP
EBITDA (TTM)
-$3.26MUSD
-2.45M GBP
Net Income (TTM)
-$3.3MUSD
-2.46M GBP
EBITDA Margin
-177%
Profit Margin
-179%
PS Ratio
14.4
PB Ratio
8.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Arron Tolley
open_in_new
Employees
30
Founded
2008
Website
aptamergroup.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 8.7% | -9% | -1.1% | -30% | -30% | 98% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
APTA
Aptamer Group PLC Ordinary Shares
ISIN: GB00BNRRP542
Shares Out.:
Shares Outstanding:
3.455B1
Shares Float:
2.83B2
|
0.6250 GBX |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Aptamer Group PLC
Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: VRNA
|
$9.22B
34K%
|
-
|
|
NASDAQ: IMCR
|
$1.42B
5K%
|
-
|
|
NASDAQ: CMPS
|
$1.13B
4K%
|
-
|
|
LSE: OXB
|
$975.48M
4K%
726.61M GBP
|
-
|
|
OTCMKTS: SLNCF
|
$265.93M
897%
|
-
|
|
LSE: DXRX
|
$196.04M
635%
146.03M GBP
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
684K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
599K%
|
19.0
|
|
EBR: ARGX
|
$48.08B
180K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.48B
167K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$43.01B
161K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.72B
160K%
33.71B CHF
|
37.2
|
chevron_leftBack